Clarus view 7 months ago Hasn't been a peep from Clarus recently.... a reminder of what they thought 7 months ago.....
.
Clarus expects StageZero to soon announce partners for the launch of its testing platform, such as cancer treatment clinics and hospital networks. The quality of these will be critical to Aristotle’s commercial credibility with potential commercial customers. The model could be that SZLS provides the testing platform and receives remuneration for these services, and then patients who test positive via Aristotle to the local cancer clinic or hospital partner for review, follow-up examination (probably imaging and / or tissue biopsy ) and treatment.
In the meantime, SZLS continues to handle large-volume Covid-19 test orders (PCR and serology tests) from private companies that bear the costs, including healthcare providers (retirement homes, hospitals, companies that provide nurses for home care, etc.), travel / Transport companies and other organizations that employ high-risk employees (city councils, meat packers). Covid-19 tests will support the company until Aristotle launches, but will become less important in the long term. However, the Covid-19 tests are currently attracting the attention of investors.
Outlook for the current 2020 financial year
For the current 2020 financial year, Clarus expects revenues of around 7.2 million US dollars in 2020 (almost exclusively from Covid-19 tests). SZLS generated approximately $ 1 million in the first half of Q3 2020. With Covid testing volume and revenue expected to accelerate, Clarus expects Q3 revenue of $ 2.7 million and an additional $ 4 million in Q4.